Zura Bio Completes Enrollment in Two Phase 2 Trials Despite Rising Losses
On August 11, Zura Bio (NASDAQ:ZURA) reported second-quarter results highlighting both progress and financial challenges. The company successfully completed enrollment for two Phase 2 trials of its lead drug tibulizumab ahead of schedule—TibuSHIELD in hidradenitis suppurativa with 247 participants and TibuSURE in systemic sclerosis with 91 participants. Topline data are expected by late 2026 and early 2027, respectively. Zura also announced plans to expand tibulizumab’s use into polymyalgia rheumatica after receiving supportive feedback from the FDA. The company holds $205.1 million in cash as of June 30, which it claims will fund operations through at least late 2028—allowing for three trial readouts without needing additional financing. However, financials show a significant increase in losses due to rising R&D costs. Net loss widened to $26.3 million ($0.21 per share) from $16.0 million ($0.17 per share) the previous year as Zura accelerates its trials. Institutional ownership has declined, and short interest remains high at 15.95% of the float.
Topics: financial losses Phase 2 enrollment milestones tibulizumab